Potential Limitations of the NSG Humanized Mouse as a Model System to Optimize Engineered Human T cell Therapy for Cancer

被引:30
作者
Alcantar-Orozco, Erik M. [1 ]
Gornall, Hannah [1 ]
Baldan, Vania [1 ]
Hawkins, Robert E. [1 ]
Gilham, David E. [1 ]
机构
[1] Univ Manchester, Dept Med Oncol, Clin & Expt Immunotherapy Grp, Inst Canc Sci,Manchester Acad Healthcare Sci Ctr, Manchester M20 4BX, Lancs, England
基金
英国生物技术与生命科学研究理事会;
关键词
VERSUS-HOST-DISEASE; ADOPTIVE IMMUNOTHERAPY; LENTIVIRAL VECTORS; GENE-TRANSFER; MEMORY CELLS; NAIVE RATHER; IL-15; TRANSDUCTION; REGRESSION; SUPERIOR;
D O I
10.1089/hgtb.2013.022
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The genetic modification of peripheral blood lymphocytes using retroviral vectors to redirect T cells against tumor cells has been recently used as a means to generate large numbers of antigen-specific T cells for adoptive cell therapy protocols. However, commonly used retroviral vector-based genetic modification requires T cells to be driven into cell division; this potent mitogenic stimulus is associated with the development of an effector phenotype that may adversely impact upon the long-term engraftment potential and subsequent antitumor effects of T cells. To investigate whether the cytokines used during culture impact upon the engraftment potential of gene-modified T cells, a humanized model employing T cells engrafted with a MART-1-specific T cell receptor adoptively transferred into NOD/Shi-scid IL-2r gamma(-/-)(NSG) immune-deficient mice bearing established melanoma tumors was used to compare the effects of the common gamma chain cytokines IL-2, IL-7, and IL-15 upon gene-modified T cell activity. MART-1-specific T cells cultured in IL-7 and IL-15 demonstrated greater relative in vitro proliferation and viability of T cells compared with the extensively used IL-2. Moreover, the IL-15 culture prolonged the survival of animals bearing melanoma tumors after adoptive transfer. However, the combination of IL-7 and IL-15 produced T cells with improved engraftment potential compared with IL-15 alone; however, a high rate of xenogeneic graft-versus-host disease prevented the identification of a clear improvement in antitumor effect of these T cells. These results clearly demonstrate modulation of gene-modified T cell engraftment in the NSG mouse, which supports the future testing of the combination of IL-7 and IL-15 in adoptive cell therapy protocols; however, this improved engraftment is also associated with the long-term maintenance of xeno-reactive T cells, which limits the ultimate usefulness of the NSG mouse model in this situation.
引用
收藏
页码:310 / 320
页数:11
相关论文
共 45 条
[1]   Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2Rγnull Mice Display a T-Effector Memory Phenotype [J].
Ali, Niwa ;
Flutter, Barry ;
Rodriguez, Robert Sanchez ;
Sharif-Paghaleh, Ehsan ;
Barber, Linda D. ;
Lombardi, Giovanna ;
Nestle, Frank O. .
PLOS ONE, 2012, 7 (08)
[2]   Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy [J].
Bendle, Gavin M. ;
Linnemann, Carsten ;
Hooijkaas, Anna I. ;
Bies, Laura ;
de Witte, Moniek A. ;
Jorritsma, Annelies ;
Kaiser, Andrew D. M. ;
Pouw, Nadine ;
Debets, Reno ;
Kieback, Elisa ;
Uckert, Wolfgang ;
Song, Ji-Ying ;
Haanen, John B. A. G. ;
Schumacher, Ton N. M. .
NATURE MEDICINE, 2010, 16 (05) :565-U98
[3]   IL-15 promotes the survival of naive and memory phenotype CD8+ T cells [J].
Berard, M ;
Brandt, K ;
Paus, SB ;
Tough, DF .
JOURNAL OF IMMUNOLOGY, 2003, 170 (10) :5018-5026
[4]   Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates [J].
Berger, Carolina ;
Jensen, Michael C. ;
Lansdorp, Peter M. ;
Gough, Mike ;
Elliott, Carole ;
Riddell, Stanley R. .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (01) :294-305
[5]   Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients [J].
Besser, Michal J. ;
Shapira-Frommer, Ronnie ;
Treves, Avraham J. ;
Zippel, Dov ;
Itzhaki, Orit ;
Hershkovitz, Liat ;
Levy, Daphna ;
Kubi, Adva ;
Hovav, Einat ;
Chermoshniuk, Natalia ;
Shalmon, Bruria ;
Hardan, Izhar ;
Catane, Raphael ;
Markel, Gal ;
Apter, Sara ;
Ben-Nun, Alon ;
Kuchuk, Iryna ;
Shimoni, Avichai ;
Nagler, Arnon ;
Schachter, Jacob .
CLINICAL CANCER RESEARCH, 2010, 16 (09) :2646-2655
[6]   Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer [J].
Birkholz, K. ;
Hombach, A. ;
Krug, C. ;
Reuter, S. ;
Kershaw, M. ;
Kaempgen, E. ;
Schuler, G. ;
Abken, H. ;
Schaft, N. ;
Doerrie, J. .
GENE THERAPY, 2009, 16 (05) :596-604
[7]   A novel flow cytometric assay for evaluating cell-mediated cytotoxicity [J].
Burkett, MW ;
Weaver, KAS ;
Strobl, S ;
Baseler, M ;
Malyguine, A .
JOURNAL OF IMMUNOTHERAPY, 2005, 28 (04) :396-402
[8]   IL-7+IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo [J].
Cha, Esther ;
Graham, Laura ;
Manjili, Masoud H. ;
Bear, Harry D. .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (02) :359-369
[9]   IL-7 adjuvant treatment enhances long-term tumor antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector [J].
Colombetti, Sara ;
Levy, Frederic ;
Chapatte, Laurence .
BLOOD, 2009, 113 (26) :6629-6637
[10]   Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens [J].
Dudley, Mark E. ;
Yang, James C. ;
Sherry, Richard ;
Hughes, Marybeth S. ;
Royal, Richard ;
Kammula, Udai ;
Robbins, Paul F. ;
Huang, JianPing ;
Citrin, Deborah E. ;
Leitman, Susan F. ;
Wunderlich, John ;
Restifo, Nicholas P. ;
Thomasian, Armen ;
Downey, Stephanie G. ;
Smith, Franz O. ;
Klapper, Jacob ;
Morton, Kathleen ;
Laurencot, Carolyn ;
White, Donald E. ;
Rosenberg, Steven A. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5233-5239